WOCKPHARMA2,219.90

Wockhardt Ltd.

· Pharma & Health
₹ CrorePeersBIOCONSYNGENEASTERDMGLANDPPLPHARMACOHANCELALPATHLABNATCOPHARMMcap ₹35,962 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Returns
Return on Common Equity-12.64-1.014.034.03
Return on Assets-6.17-0.702.312.31
Return on Capital Employed-3.792.896.086.08
Return on Invested Capital-3.492.945.247.20
Margins
EBITDA Margin1.3913.0519.3321.66
Operating Margin-6.585.8412.6012.60
Incremental Operating Margin168.2268.98
Pretax Margin-15.01-0.537.0612.99
Net Income Margin-16.87-1.895.9011.62
Net Income to Common Margin-16.55-1.566.3111.48
FCF Margin5.72-3.857.537.53
Additional
Effective Tax Rate-12.38-256.2516.3910.58
Sustainable Growth Rate-12.64-1.014.034.03
Incremental Operating Margin %168.2268.9863.35
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.